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Dear Sir,  
Blood transfusion is a life-saving process for anaemic, surgical, oncological and 
severely injured patients. However, an increasing number of reports suggest that 
transfusion of stored human blood may also pose some risks and can be associated 
with adverse clinical outcomes, including infections and tumour recurrence, which, in 
some studies, have been found to be more frequent as blood storage time increases. 
Nevertheless, retrospective analyses on large numbers of patients do not support the 
notion that increasing median duration of red blood cell storage is associated with an 
enhanced risk of postoperative mortality. Appropriate randomised, controlled clinical 
trials will be crucial to address the controversial issue of the effect of the duration of 
blood storage on outcomes. The proposed detrimental effects of prolonged blood 
storage have been attributed in part to haemolysis of packed erythrocytes stored for a 
prolonged period, which leads to an increased oxyhaemoglobin concentration and nitric 
oxide (NO) scavenging. Indeed, the haemoglobin level in the storage bag supernatant 
was found to be higher after 40 days of storage than after 3 days of storage, indicating 
increased haemolysis, and infusion of 40-day packed erythrocytes was recently 
suggested to lead to increased NO production from endothelial nitric oxide synthase 
(NOS), as a compensatory mechanism for reduced NO bioavailability caused by 
plasma oxyhaemoglobin scavenging of NO. NOS and arginase use L-arginine as a 
common substrate and the presence of increased levels of these enzymes could lead 
to L-arginine depletion and its ensuing physiological effects, including inhibition of T-
cell function, as L-arginine is required for T-cell activation and proliferation. Human 
erythrocytes express an active and functional endothelial-type NOS as well as 
arginase. Thus, increased haemolysis might be an important aspect in blood 
transfusion, leading to elevated levels of arginase and NOS, and, thereby, to L-arginine 
depletion that could eventually elicit adverse outcomes. We took 10-mL samples of 
units of blood after different periods of storage and centrifuged them at 1,200 rpm for 
12 min at room temperature. Free arginase activity and the haemolytic index were 
determined using standard methods of measuring the conversion of arginine into 
ornithine and urea (arginase activity) and the absorbance of free haemoglobin in the 
plasma (haemolytic index). We found statistically significant increases in haemolysis 
and free arginase activity along the storage time of the packed erythrocyte bags (Table 
I). Because transfusion of contaminating leucocytes is now considered to be potentially 
harmful, leucocyte reduction, by which white blood cells are removed before 
transfusion, has been incorporated into the practice of most medical centres around the 
world. However, although leucoreduced units of packed red blood cells contain fewer 
than 5×106 white blood cells, it should be noted that neutrophils, which undergo 
spontaneous cell death, constitutively express large amounts of arginase and even 
small contamination of packed red cell bags by neutrophils might, therefore, produce 
significant levels of arginase activity, apart from that derived from the red cells 
themselves. This is a possible explanation for the relatively greater increase in 
arginase level than in haemolytic index (Table I). Arginase is gaining momentum as a 
key player in the control of L-arginine availability and the regulation of several 
physiological processes, including the immune system. Thus, high levels of free 
arginase following blood transfusion could underlie many of the deleterious outcomes, 
including immunosuppression and infectionrelated processes associated with 
transfusion of blood stored for long periods. Although arginase has a short half-life of 
only a few hours in human blood, it might act in early stages of immunosuppression. 
Our finding of raised levels of free arginase in blood stored for long periods could have 
implications for patients in whom immunosuppression is a major challenge.  
Of course, in vitro findings cannot be translated automatically to clinical outcomes and 
further investigation is required. Current Food and Drug Administration regulations 
allow transfusion of packed red blood cells stored for up to 42 days. Nevertheless, our 
data draw attention to the fact that levels of free arginase increase in packed red blood 
cell units with increasing storage time, which could be a concern when transfusing 
patients, particularly those such as cancer patients who are immunodepressed, given 
the potential adverse effects. 
 
 
Table I - Free arginase activity and haemolytic index in units of human packed red 
blood cells at different days of storage.  
Days of storage         Arginase activity (mU/mL)      Haemolytic index  
6-10                           62.1±15.5                               43.7±8.9  
11-15                         55.0±8.0                                 55.5±8.9  
16-20                         88.3±33.4                               53.4±10.5  
21-25                         220.6±64.5**                          135.5±55.7*  
26-30                         402.9±52.6**                          147.2±37.3**  
Data are means ± SD (n ≥7). Asterisks indicate values that are significantly different 
from those of the values for 6-10 days of storage, according to a Student's t-test. *P 
<0.01. 
